The Broad Institute of MIT and Harvard’s Cancer Dependency Map Consortium, an academic-industrial partnership program that was first announced in 2019, is accelerating its research into tumor vulnerabilities and identifying key biomarkers. As the consortium enters a new phase, a total of 19 pharmaceutical and biotechnology organizations are partnering in this project.
The Cancer Dependency Map Consortium supports the Broad’s Cancer Dependency Map (DepMap) initiative, which aims to accelerate precision cancer medicine by creating a comprehensive map of tumor vulnerabilities. DepMap is using large-scale functional genomics and PRISM therapeutic agent response profiling across large panels of cancer models to create a systematic overview — or “map” — of the genetic dependencies and compound sensitivities of each type of cancer and the predictive biomarkers that point to patient populations most likely to benefit.
